Amneal Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Amneal Pharmaceuticals (Bridgewater, NJ): 39 reconciled FDA prescription therapies (37.8% 2025 to 2030 cliff risk), $735.6M 2024 CMS Part D & Medicaid spend, and 32 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBridgewater, NJ
Reconciled FDA Portfolio Therapies39
2025 to 2030 Patent-Cliff Revenue Exposure37.8%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$735.6M
2024 Medicare Part D Spend$527.6M
2024 Medicaid Spend$208.0M
California HCAI SB 17 Filings32 WAC filings (max 125.0% 2-yr change)